In just one year of using SOPHiA DDM™ HRD,
Dasa reaches 2,000 samples analyzed
BOSTON and LAUSANNE, Switzerland, May 8, 2023
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
software company and the leader in data-driven
medicine, celebrates today with longstanding partner, Dasa,
the largest integrated healthcare network in Brazil, as it reaches a milestone of 2,000
samples analyzed for HRD status. This milestone comes just one year
after implementing the SOPHiA DDM™ Homologous Recombination
Deficiency (HRD) Solution.
Renowned in Brazil and abroad,
Dasa serves more than 20 million patients per year – including
approximately 10% of the Brazilian population.
"With such a large regional network, we needed a partner like
SOPHiA GENETICS to help improve our workflow efficiency and help us
implement HRD testing," said Ana Gabriela
de Oliveira, Sr. Business Unit Manager, Dasa. "The
decentralized approach of SOPHiA GENETICS has enabled us not only
to implement new testing, but to increase our scalability and
output. In addition, the powerful analytics of the SOPHiA DDM™
platform has helped us to maximize genomic insights from tested
profiles and advance our research capabilities."
Today's achievement has been nearly a decade in the making. In
2016 Dasa chose SOPHiA GENETICS to build the original workflow for
its genomics lab. The partnership progressed in 2020 when Dasa
implemented SOPHiA DDM™ Radiomics and Trial Match solutions to
create the first multimodal approach in the region.
In 2021, the companies once again expanded their partnership
when Dasa and SOPHiA GENETICS collaborated to offer the first
decentralized HRD (Homologous recombination deficiency) analytics
solution in Latin America. Dasa
then implemented the SOPHiA DDM™ Homologous Recombination
Deficiency (HRD) Solution in March
2022.
"Dasa's milestone of 2,000 samples tested in just one year is a
true testament to the value of the functionality of the SOPHiA DDM™
HRD Solution," said Ken Freedman,
Chief Revenue Officer, SOPHiA
GENETICS. "Reaching such a milestone demonstrates the
success of our expanding partnership and the value our platform can
provide to our partners, as well as the value that they provide by
helping to democratize data-driven medicine for all as we continue
to scale."
To learn more about the SOPHiA DDM™ HRD solution, visit the
SOPHiA GENETICS HRD page.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook,
and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM ™ Radiomics is a technology and concept in
development and may not be available for sale. The information in
this press release is about products that may or may not be
available in different countries and, if applicable, may or may not
have received approval or market clearance by a governmental
regulatory body for different indications for use. Please contact
support@sophiagenetics.com to obtain the appropriate product
information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dasa-expands-its-capabilities-with-sophia-genetics-301824701.html
SOURCE SOPHiA GENETICS